Argenx stock hits new 52-week high as Q2 2026 growth stays in focus

Argenx stock has climbed to a fresh 52-week high, with investors focusing on strong Q2 2026 revenue and earnings growth while a new AI collaboration adds to the long-term story.

Argenx SE (ISIN NL0010832176) stock reached a new 52-week high of 1,069.00 USD during intraday trading on September 2, 2026, after previously closing at 1,028.51 USD on NASDAQ.A MarketBeat price alert highlighted the move, which keeps the strong Q2 2026 figures firmly in view for investors.

Stock pushes to a new yearly high

According to the latest quote overview from MarketBeat on September 2, 2026, Argenx shares traded as high as 1,069.00 USD intraday and last changed hands at 1,057.92 USD, compared with the previous close of 1,028.51 USD.The same snapshot described the print as a new 1-year high for the NASDAQ listing. For investors, the price level stands close to the 52-week high, signaling confidence in the company’s growth profile.

A separate market overview from MarketScreener showed Argenx at 1,029.50 USD on CBOE with a 5-day change of minus 0.25 percent and a year-to-date gain of 2.05 percent as of September 2, 2026.The MarketScreener quote underlines that the stock’s latest push to a one-year high comes after only modest gains for 2026 as a whole, which may leave room for further rerating if fundamentals continue to deliver.

Q2 2026 figures and valuation in the spotlight

Argenx’s operational momentum is reflected in recent coverage citing its second quarter of 2026 performance. One healthcare-focused analysis on Yahoo Finance reported that Argenx delivered 18 consecutive quarters of revenue growth, with sales rising 60 percent year over year in Q2 2026 and 17 percent sequentially versus Q1 2026.The article described Q2 2026 revenue growth as a key driver of the stock’s long-term story.

The same Yahoo Finance piece noted that Argenx reported earnings of 472 million USD in Q2 2026, nearly doubling profit compared with the prior-year quarter.It also highlighted that operating margins expanded alongside the top-line growth, suggesting improved profitability as the company scales its immunology portfolio. For investors, the combination of 60 percent revenue growth and a near 100 percent earnings increase versus Q2 2025 positions Q2 2026 as a pivotal quarter in the current reporting cycle.

On the valuation side, the same coverage pointed out that Argenx shares are trading at roughly 37.5 times forward earnings based on current estimates.This multiple places Argenx toward the higher end of the large-cap biotech peer group, but the 18-quarter revenue growth streak and robust Q2 2026 earnings trajectory provide context for why the market is willing to pay a premium. The current 1-year high, therefore, reflects both strong fundamentals and high expectations for continued expansion.

AI partnership adds a strategic angle

Beyond quarterly figures, Argenx has moved to deepen its use of artificial intelligence in drug discovery. On September 2, 2026, BenchSci announced a two-year enterprise agreement with Argenx to deploy EMET, its agentic research environment for preclinical drug discovery.The Business Wire release distributed via Yahoo Finance described Argenx as a global immunology innovation company and framed the deal as a way to accelerate preclinical decision-making.

For Argenx, integrating EMET into its research workflows could support more efficient identification and prioritization of antibody candidates, potentially shortening the time from early research to clinical development. While the agreement does not provide immediate revenue figures, it sits alongside the strong Q2 2026 numbers and may help sustain the company’s 18-quarter revenue growth streak by enhancing its R&D engine. Investors monitoring Argenx stock can therefore view the AI partnership as a qualitative complement to the quantitative earnings momentum already visible in the latest results.

Leading product and immunology focus

Argenx’s business is centered on antibody-based therapies for autoimmune diseases, with its flagship product being efgartigimod, marketed in multiple indications for generalized myasthenia gravis and other conditions. Recent commentary on the company’s performance has tied part of the Q2 2026 revenue growth to continued expansion of efgartigimod across geographies and treatment settings, although specific product-level numbers were not broken out in the available sources. The strong 60 percent year-over-year revenue increase in Q2 2026 nonetheless suggests that its core immunology franchise is scaling effectively.

Stock level and investor takeaway

As of the most recent completed trading session on September 2, 2026, Argenx stock closed at 1,028.51 USD on NASDAQ according to the Yahoo Finance quote snapshot, with after-hours indications holding at the same level.The quote overview places this closing price below the intraday high of 1,069.00 USD reported by MarketBeat but still within the upper part of the 52-week range, underlining the stock’s strong position after the latest quarterly report. With year-to-date performance at just above 2 percent on CBOE and Q2 2026 revenue up 60 percent year over year, the current price encapsulates both substantial growth already delivered and expectations for further progress.

Argenx stock at a glance

• Company: Argenx SE
• ISIN: NL0010832176
• Ticker: ARGX
• Trading venue: NASDAQ
• Price (as of September 2, 2026, 16:00): 1,028.51 USD
• Market capitalization: 64.00 billion USD (as of September 2, 2026)
• Sector / Industry: Biotechnology / Immunology therapeutics
• Index membership: NASDAQ indices